Research reveals that CB1r activation impacts BDNF levels and behavioral changes during REM sleep deprivation, suggesting interactions with anxiety and depression.
Key Points
48-hour REM sleep deprivation increased anxiety and depressive-like behaviors, while reducing locomotion and pain threshold levels.
Injecting varying doses of ACPA, a CB1r agonist, dose-dependently restored behavioral functions and elevated BDNF levels in the hippocampus.
Analysis using Pearson correlation showed BDNF levels have an inverse relation to anxiety and depressive-like behaviors, yet a direct relation to locomotor activity and pain threshold.
Findings suggest that CB1r activation interacts with REM sleep deprivation effects, indicating potential pathways to modulate anxiety and depression.